NCT02284828View on ClinicalTrials.gov

Effects of Eslicarbazepine Acetate (BIA 2-093) on Cognition and Psychomotor Function

PHASE1CompletedINTERVENTIONAL

Enrollment

26

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

November 30, 2007

Study Completion Date

November 30, 2007

Conditions

Epilepsy

Interventions

DRUG

BIA 2-093

All Listed Sponsors

lead

Bial - Portela C S.A.

INDUSTRY

NCT02284828 - Effects of Eslicarbazepine Acetate (BIA 2-093) on Cognition and Psychomotor Function | Biotech Hunter | Biotech Hunter